Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Bupivacaine for Breast Reconstruction Pain
NCT03393117Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: total post-operative narcotic utilization at 72 hours. Planned start Mar 2018; status: withdrawn.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03393117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393117.